Skip to main content
AkademIndex

Products

For developers

AkademBaseOpen API for the ecosystem
← Back to work

Works cited by this work

27 works

Work: Catumaxomab

  1. Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients

    Peter Ruf, Michael Kluge, Michael Jäger +7

    Article20103 citations
    ABI

  2. Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody

    Peter Ruf, Horst Lindhofer

    Article20013 citations
    ABI

  3. Effective Relief of Malignant Ascites in Patients with Advanced Ovarian Cancer by a Trifunctional Anti-EpCAM × Anti-CD3 Antibody: A Phase I/II Study

    Alexander Burges, Pauline Wimberger, Carolin Kümper +15

    Article20073 citations
    ABI

  4. Simultaneous Activation of T Cells and Accessory Cells by a New Class of Intact Bispecific Antibody Results in Efficient Tumor Cell Killing

    Reinhard Zeidler, G. Reisbach, Barbara Wollenberg +4

    Article19992 citations
    ABI

  5. Pattern and prognostic factors in patients with malignant ascites: a retrospective study

    Abraham Ayantunde, SL Parsons

    Article20072 citations
    ABI

  6. Lysis of Prostate Carcinoma Cells by Trifunctional Bispecific Antibodies (αEpCAM × αCD3)

    Rainer Riesenberg, Alexander Büchner, Heike Pohla +1

    Article20012 citations
    ABI

  7. The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells

    Reinhard Zeidler, Josef Mysliwietz, M Csanády +5

    Article20002 citations
    ABI

  8. Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer

    Peter Ruf, Olivier Gires, Michael Jäger +3

    Article20072 citations
    ABI

  9. Immunomonitoring Results of a Phase II/III Study of Malignant Ascites Patients Treated with the Trifunctional Antibody Catumaxomab (Anti-EpCAM × Anti-CD3)

    Michael Jäger, A. Schoberth, Peter Ruf +8

    Article20112 citations
    ABI

  10. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

    M. M. Heiss, P. Murawa, P. Koralewski +17

    Article20102 citations
    ABI

  11. Humoral response to catumaxomab correlates with clinical outcome: Results of the pivotal phase II/III study in patients with malignant ascites

    Marion Ott, Frederik Marmé, Gerhard Moldenhauer +6

    Article20112 citations
    ABI

  12. Catumaxomab

    R. Linke, Anke Klein, Diane Seimetz

    Review articleIntraperitoneal and Appendiceal MalignanciesmAbs20101 citations
    ABI

  13. Untitled

    Other1 citations
    ABI

  14. Untitled

    Other1 citations
    ABI

  15. Untitled

    Other1 citations
    ABI

  16. Untitled

    Other1 citations
    ABI

  17. Untitled

    Other1 citations
    ABI

  18. Untitled

    Other1 citations
    ABI

  19. Untitled

    Other1 citations
    ABI

  20. Untitled

    Other1 citations
    ABI

  21. Untitled

    Other1 citations
    ABI

  22. Untitled

    Other1 citations
    ABI

  23. Untitled

    Other1 citations
    ABI

  24. Untitled

    Other1 citations
    ABI

  25. Untitled

    Other1 citations
    ABI